Simpa S. Salami, M.D., M.P.H. is a fellowship-trained, board-certified Urologic Oncologist and Associate Professor of Urology at the University of Michigan. He obtained his MD from the College of Medicine, University of Ibadan, Nigeria. He a completed a Master of Public Health program at Harvard University, General Surgery Internship at the Brigham and Women’s Hospital in Boston, Urology Residency at Hofstra Northwell Health School of Medicine in New York, and Urologic Oncology Fellowship at the University of Michigan in Ann Arbor, Michigan. Dr. Salami is a translational surgeon-scientist whose research interests are in early detection and staging of prostate and kidney cancer. The goal of his research is to develop novel cancer biomarkers to overcome tumor heterogeneity and multifocality as well as elucidate optimal paradigms for early detection of urologic cancers, risk stratification, prognostication, and prediction of treatment response. Dr. Salami is a recipient of numerous awards including the: Harvard University Presidential Scholar, Prostate Cancer Foundation Young Investigator, American Urological Association (AUA) Urology Care Foundation (UCF) Research Scholar, AUA UCF Rising Stars in Urologic Research, Harold Amos Medical Faculty Development Fellowship, Rogel Cancer Center Scholar, Society of Urologic Oncology Young Investigator, and NCI R37 MERIT Awards. Most recently, he was named an inaugural Biden White House Cancer Moonshot Scholar. He has served on several National guideline committees, such as the AUA Prostate Cancer Early Detection Guidelines, the NCCN Prostate Cancer Early Detection Guidelines, and the Society of Nuclear Medicine and Imaging PSMA PET Appropriate Use Criteria Working Group. His research is supported by multiple sources and includes funding from the Department of Defense, National Cancer Institute, and the Prostate Cancer Foundation.

Imaging, liquid and tissue-based biomarkers